Drug intelligence / Profile preview

VSV-GP154

Development stage: Phase 1
Lead developer: Boehringer Ingelheim
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

VSV-GP154 is a VSV-GP-based cancer vaccine that preferentially replicates in pancreatic adenocarcinoma cells with KRAS G12D or KRAS G12V mutations. It is designed to induce immunogenic cell death in tumors and stimulate immune cell recruitment. It is part of a heterologous prime-boost vaccine strategy used in combination with other treatments like ATP150/ATP152 and Ezabenlimab for treating KRAS mutated pancreatic ductal adenocarcinoma.

Other names: VSV-GP-based cancer vaccine

Targets

LDLR (Low-density lipoprotein receptor)

Beyond the preview

Go deeper on VSV-GP154.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VSV-GP154.